Skip to main content
. 2024 Aug 8;10(5):e144. doi: 10.1192/bjo.2024.727

Fig. 3.

Fig. 3

(a) Risk estimates and 95% CI of diabetes risk by study month among individuals with severe MDD treated continuously with aripiprazole (red) or olanzapine (blue). Vertical line ranges correspond to 95% pointwise CI. (b) Differences in (left panel) and ratios of (right panel) diabetes risk by study month among individuals with severe MDD treated continuously with olanzapine compared with the risk of treatment with aripiprazole (reference group)